Neil Schwartz

Neil Schwartz has been working in the field of research and development since 2005. Neil began their career as a PhD student at McGill University, where they worked with Dr. ED Ruthazer and demonstrated that activity dependent transcription regulates the ability of the nervous system to adapt to environmental changes. In 2010, they began their postdoctoral work at Stanford University School of Medicine with Dr. Rob Malenka, where they determined that motivation to work for natural rewards is decreased in the pathology of chronic pain, and established that preventing pathological changes in striatal circuitry rescues motivated behavior. In 2014, they moved to UCSF to work with Dr. Howard Fields, where they established that the pathology of chronic pain leads to changes in cortico-striatal circuits that determine approach-avoidance choices. In 2017, they joined Epiodyne as Vice President Research & Development and Head of in vivo pharmacology.

Neil Schwartz attended McGill University, where they obtained a Doctor of Philosophy in Neuroscience.